AstraZeneca acquires DSM Biologics manufacturing facility in Canada
Royal DSM N.V. today announces that AstraZeneca (LSE: AZN, NYSE: AZN) has acquired the biologics manufacturing facility in Montreal, Canada, from DSM Biologics Inc. This transaction will lead to a small book profit for DSM.
The facility, occupying 66,000 sq. ft, will be used to manufacture antibody drug candidates for clinical trials and will serve the whole of the AstraZeneca group. Work will now start to re-commission the facility, and AstraZeneca plans to commence full scale production in 2009.
Leendert Staal, President and CEO of DSM Pharmaceutical Products comments: “ We are very pleased with this transaction, hereby completing an important step in our Biologics strategy”.
As announced in December 2005, DSM mothballed the Montreal facility as part of its strategy for DSM Biologics. Core to this strategy is the development and out-licensing of a new manufacturing technology platform based on the PER.C6® human cell line, in a joint venture with the Dutch biotechnology company Crucell N.V (Euronext, NASDAQ: CRXL). DSM and its partner Crucell have recently announced a breakthrough in production yields, achieving 10g/L in the fermentation of monoclonal antibodies, using the PER.C6® technology platform, and stating a target of 20g/L for their near term development efforts.
Leendert Staal continues: “We have a strong focus on technology development, and jointly with our partner Crucell have recently established Percivia, a new company in Cambridge (MA – USA), for the sole purpose of developing the PER.C6® platform. We are developing our manufacturing facility in Groningen (Netherlands) as center of excellence for the scale-up and use of new PER.C6 technologies. The Montreal facility did not fit in this strategy ”.
About DSM Biologics
DSM Biologics, a business unit of DSM Pharmaceutical Products, is a leading provider of manufacturing technology and services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V., to license the high-producing PER.C6® human cell line as a production platform for recombinant proteins and monoclonal antibodies. DSM Biologics’ FDA-approved facility in Groningen, The Netherlands, was established in 1986 and has a strong track record in using a broad range of cell lines (PER.C6®, CHO, hybridoma, etc.) in biopharmaceutical manufacturing, and has a wide range of experience using multiple manufacturing (batch, fed-batch and continuous perfusion) and purification techniques. The combination of the PER.C6® human cell line and DSM’s manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market. For more information, please visit www.dsmbiologics.com.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.